ClinicalTrials.gg
RecruitingNCT07750223Updated Aug 6, 2026

Cognitive Effects of Hesperidin in Overweight/Obese Older Adults

An interventional study of Hesperidin in Cognitive Dysfunction and Overweight and Obesity, sponsored by Min Hou. Recruiting at 1 site in China. Open to participants aged 55 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Min Hou · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Feb 2026, registered Jul 2026).
  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
55 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 310 studies in Cognitive Dysfunction with a site in China — 144 open to participants now, 156 under way, 8 of them phase 3. Cognitive Dysfunction · China.

Planned enrollment
99th of 191
105 · median 110
Started
2026
with 44 others
No phase
139 of 310
61 open now
Primary completion
2027-03
later than 88 of 155 live
Registered
287th of 310
by date

Among the 310 studies in Cognitive Dysfunction with a site in China, this one is the 99th largest by planned enrollment of the 191 interventional ones that give a count, is one of 45 that started in 2026, is one of 139 with no phase, reaches primary completion later than 88 of the 155 other live ones, and was the 287th registered.

Cognitive Dysfunction

3,883 studies on the registry are indexed under Cognitive Dysfunction; 1,121 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

144 of the 310 studies in Cognitive Dysfunction with a site in China are open now. Recruiting first, the newest first:

138 more — sign in →

All 144 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 752 Cognitive Dysfunction studies recruiting now, 362 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 55 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 310 studies in Cognitive Dysfunction with a site in China, or all of them as a file.
02

Study summary

A randomized, double-blind, placebo-controlled trial was designed to test whether two doses of hesperidin (a natural flavonoid from citrus fruits) improve cognitive function in overweight and obese older adults.

A total of 105 participants, aged 55-75 years with a BMI ≥24 kg/m² or elevated waist circumference, will be randomly assigned to one of three 10-week treatments: placebo, low-dose hesperidin (300 mg/day), or high-dose hesperidin (600 mg/day).

The primary aim is to see if hesperidin supplementation enhances cognitive performance - specifically executive function, memory, and attention - and to explore any dose-response relationship.

Secondary aims include examining changes in gut microbiota composition and related metabolites, as well as exploring potential mechanisms behind any observed effects.

The findings are expected to provide scientific evidence on whether hesperidin could serve as a nutritional strategy to support cognitive health in this population.

03

Conditions studied

  • Cognitive Dysfunction
  • Overweight and Obesity

Keywords

  • Hesperidin
  • Cognitive Function
  • Citrus Flavonoids
  • Gut Microbiota
  • Nutritional Intervention
  • Middle-aged and Elderly
  • Randomized Controlled Trial
04

Who can participate

Ages eligible
55 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 55-75 years
  • ≥ 24 kg/m² or waist circumference ≥ 90 cm (men) / ≥ 85 cm (women)
  • Willing to participate and sign

Exclusion criteria

Exclusion Criteria:

  • score \< 20
  • History of neurological diseases (Parkinson's, Alzheimer's, stroke, etc.)
  • Malignant tumors, severe liver/kidney/gastrointestinal diseases
  • Use of weight-loss drugs or antidepressants (except statins) within recent months
  • Strict vegetarians, binge eating disorder, heavy alcohol consumption
  • Participation in other intervention studies
  • Other conditions judged by investigators as unsuitable
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
105 participants (estimated)

Study arms

  • Placebo comparator
    Placebo Group

    Participants receive 2 placebo capsules (corn starch 600 mg/day) daily for 10 weeks. Capsules are identical in appearance, smell, and packaging to hesperidin capsules.

    Dietary Supplement: Hesperidin

  • Experimental
    Low-Dose Hesperidin Group

    Participants receive hesperidin 300 mg + corn starch 300 mg (total 600 mg) daily, taken as 2 capsules for 10 weeks.

    Dietary Supplement: Hesperidin

  • Experimental
    High-Dose Hesperidin Group

    Participants receive hesperidin 600 mg daily, taken as 2 capsules for 10 weeks.

    Dietary Supplement: Hesperidin

Interventions

  • Dietary supplementHesperidin

    Oral hesperidin supplementation or matching placebo, administered as 2 capsules per day for 10 weeks. * Placebo Comparator: corn starch 600 mg/day * Low-dose: hesperidin 300 mg + corn starch 300 mg/day (total 600 mg) * High-dose: hesperidin 600 mg/day All capsules are identical in appearance, color, smell, taste, and packaging to maintain blinding. All participants undergo scheduled assessments: physical measurements (weeks 2,4,6,8), 24h dietary recall and IPAQ (every 2 weeks), weekly urine samples, fecal samples (weeks 2,4,8,10), fasting blood samples (baseline and week 10), and bi-weekly nutrition education lectures (general health education only ,no dietary restriction).

    Also known as: Citrus Flavonoid

06

What researchers measure

Primary outcomes

  1. Change in Cognitive Function Assessed by the Mini-Mental State Examination (MMSE)

    Units on a Scale (0 to 30 points).Higher scores indicate better cognitive function. Scores ≥25 are generally considered normal; scores \<24 suggest cognitive impairment.

    Time frame: Baseline to Week 10

  2. Change in Cognitive Function Assessed by the Montreal Cognitive Assessment (MoCA)

    Units on a Scale (0 to 30 points).Higher scores indicate better cognitive function. Scores ≥26 are considered normal; scores 18-25 indicate mild cognitive impairment; scores 10-17 indicate moderate impairment; scores \<10 indicate severe impairment.

    Time frame: Baseline to Week 10

  3. Change in Cognitive Function Assessed by the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)

    Units on a Scale (0 to 30 points). Higher scores indicate worse cognitive function (greater impairment).

    Time frame: Baseline to Week 10

  4. Change in Cognitive Function Assessed by the Trail Making Test (TMT)

    Unit of Measure is Seconds. Shorter completion times indicate better cognitive function. Part B assesses executive function and cognitive flexibility; a higher TMT-B/TMT-A ratio may indicate greater impairment.

    Time frame: Baseline to Week 10

  5. Change in Cognitive Function Assessed by the Digit Symbol Substitution Test (DSST)

    Unit of Measur is Number of correct responses. Higher scores indicate better processing speed, sustained attention, and working memory.

    Time frame: Baseline to Week 10

  6. hange in Cognitive Function Assessed by the Wechsler Memory Scale (WMS)

    Raw scores for each subtest are converted to scaled scores using norm tables; scaled scores are summed to obtain the full-scale score, which is then converted to a Memory Quotient (MQ) using norm tables.Higher scores indicate better memory function. The Memory Quotient (MQ) normally ranges from 80 to 120. Scores below 80 suggest below-average memory performance; scores above 120 suggest above-average memory performance.

    Time frame: Baseline to Week 10

Secondary outcomes

  1. Change in Gut Microbiota Composition

    Changes in gut microbiota composition and diversity assessed by 16S rRNA sequencing or metagenomic analysis of fecal samples. Primary focus on alpha and beta diversity, and relative abundance of key bacterial taxa (e.g., Bifidobacterium, Lactobacillus, Akkermansia).

    Time frame: Baseline to Week 10

  2. Change in Inflammatory Markers (TNF-α, IL-6, CRP)

    Changes in serum levels of pro-inflammatory markers including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and C-reactive protein (CRP), measured by ELISA or multiplex assays.

    Time frame: Baseline to Week 10

  3. Change in Body Weight

    Change in body weight measured using standard anthropometric procedures, reported in kilograms (kg); reduction indicates improvement in weight status.

    Time frame: Baseline to Week 10

  4. Change in Waist Circumference

    Change in waist circumference measured using standard anthropometric procedures at the midpoint between the lowest rib and the iliac crest, reported in centimeters (cm); reduction indicates improvement in central adiposity.

    Time frame: Baseline to Week 10

  5. Change in Body Mass Index (BMI)

    BMI calculated as body weight in kilograms divided by the square of height in meters (kg/m²). Height was measured at baseline only using standard anthropometric procedures. Reduction in BMI indicates improvement in overall adiposity. Per Chinese BMI classification standards: 24.0-27.9 kg/m² (overweight) and ≥28.0 kg/m² (obese); the study enrolled participants with BMI ≥ 24.0 kg/m².

    Time frame: Baseline to Week 10

07

Study locations

1 of 1 sites recruiting
  • Community Health Centers in Shanghai
    Shanghai, Shanghai Municipality 200030, China
    Recruiting
08

References and documents

Publications

  • Farag S, Tsang C, Al-Dujaili EAS, Murphy PN. Effect of Polyphenol Supplementation on Memory Functioning in Overweight and Obese Adults: A Systematic Review and Meta-Analysis. Nutrients. 2024 Feb 6;16(4):474. doi: 10.3390/nu16040474. PubMed 38398799 ↗
  • Kean RJ, Lamport DJ, Dodd GF, Freeman JE, Williams CM, Ellis JA, Butler LT, Spencer JP. Chronic consumption of flavanone-rich orange juice is associated with cognitive benefits: an 8-wk, randomized, double-blind, placebo-controlled trial in healthy older adults. Am J Clin Nutr. 2015 Mar;101(3):506-14. doi: 10.3945/ajcn.114.088518. Epub 2015 Jan 14. PubMed 25733635 ↗
  • Hong Y, An Z. Hesperidin attenuates learning and memory deficits in APP/PS1 mice through activation of Akt/Nrf2 signaling and inhibition of RAGE/NF-kappaB signaling. Arch Pharm Res. 2018 Jun;41(6):655-663. doi: 10.1007/s12272-015-0662-z. Epub 2015 Sep 21. PubMed 26391026 ↗
  • Wang D, Liu L, Zhu X, Wu W, Wang Y. Hesperidin alleviates cognitive impairment, mitochondrial dysfunction and oxidative stress in a mouse model of Alzheimer's disease. Cell Mol Neurobiol. 2014 Nov;34(8):1209-21. doi: 10.1007/s10571-014-0098-x. Epub 2014 Aug 19. PubMed 25135708 ↗
  • Lamport DJ, Pal D, Macready AL, Barbosa-Boucas S, Fletcher JM, Williams CM, Spencer JP, Butler LT. The effects of flavanone-rich citrus juice on cognitive function and cerebral blood flow: an acute, randomised, placebo-controlled cross-over trial in healthy, young adults. Br J Nutr. 2016 Dec;116(12):2160-2168. doi: 10.1017/S000711451600430X. Epub 2017 Jan 16. PubMed 28091350 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Mar 2027, 13 months after the start.

Of 1,452 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 13 months is below that.

Counting every sponsor, half of 1,521 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2026
First posted
Aug 6, 2026
StartActual
Feb 1, 2026
Primary completionEst.
Mar 30, 2027
CompletionEst.
Mar 30, 2027
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07750223
Lead sponsor
Min Hou
Responsible party
Min Hou (Associate Professor / Master's Thesis Advisor, University of Glasgow) — Sponsor-investigator
First posted
Aug 6, 2026
Start date
Feb 1, 2026
Primary completion
Mar 30, 2027 (estimated)
Completion
Mar 30, 2027 (estimated)
Last update
Aug 6, 2026

Study contacts

Min Hou
Contact
minhou@sjtu.edu.cna
13121858610
ShiQi Lin
Contact
olinalin@sjtu.edu.cn
18616825727

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hesperidin

Start the discussion